J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker

J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker ntaylor Tue, 10/15/2024 - 09:14